Navigation Links
XTENT Announces First Quarter 2008 Financial Results
Date:4/28/2008

Six-month CUSTOM III long and multi-lesion clinical trial data to be

presented as late-breaking data at EuroPCR on Tuesday, May 13

MENLO PARK, Calif., April 28 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the first quarter ended March 31, 2008.

The company reported a net loss of $12.5 million, or $0.54 per share, for the first quarter of 2008, compared to a net loss of $7.9 million, or $0.55 per share, for the first quarter of 2007. The company's net loss for the first quarter of 2008 was based on weighted average shares outstanding of 22.9 million as compared to 14.5 million weighted average shares outstanding for the first quarter of 2007. At March 31, 2008, XTENT had cash, cash equivalents and short-term investments of $46.5 million.

Research and development expenses increased to $9.4 million in the first quarter of 2008 from $6.2 million for the same period in 2007, primarily due to an increased number of research and development personnel, expenditures for prototype parts and supplies as well as costs incurred for clinical trials. General and administrative expenses were $3.4 million in the first quarter of 2008 versus $2.5 million for the same period in 2007, primarily due to an increase in personnel and other related costs.

"We continue to make progress toward bringing the next generation in drug-eluting stent technology to physicians and their patients with coronary artery disease," said Gregory D. Casciaro, XTENT's President and CEO. "We are privileged to report that our CUSTOM III trial results have been selected for presentation during the Late-Breaking Trials session at the premiere international interventional cardiology meeting (EuroPCR) held n
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
2. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... officer Howie Rosen will be presenting at ... Tim Morris will be presenting at JMP Securities ... as follows: Jefferies 2015 Healthcare Conference Date: ...
(Date:5/21/2015)... Research and Markets ( ... "Market Assessment of Respiratory Diagnostics in the ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service ... market in the United States ... service provides detailed analysis of the current and ...
(Date:5/21/2015)... WASHINGTON , May 21, 2015 ... following statement regarding the Medicare Part D offsets ... Century Cures initiative: "If the 21st Century ... billions from America,s premier health program – Medicare ... it may yield down the road. ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2United States and Europe Respiratory Diagnostics Market Assessment 2015 2
... France, Oct. 8 Vical Incorporated (Nasdaq: ... new nonclinical data,demonstrating that the company,s Vaxfectin(R) adjuvant ... disease vaccines and,peptide-based cancer vaccines. Alain P. Rolland, ... will present the data today,Wednesday, October 8, at ...
... 7 Prometheus Laboratories Inc., a,specialty pharmaceutical ... PROMETHEUS(R) IBS Diagnostic, the first and only ... findings suggest measurable,differences in the expression of ... non-IBS patients. The identification of these biomarkers,combined ...
Cached Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3
(Date:5/24/2015)... 2015 ProPin is a set of ... X. Utilize ProPin to pin point locations on a map, ... , ProPin allows users to choose from 30 simplistic presets ... With on-screen controls, video editors can easily manipulate ProPin presets as ... mark with absolute ease. , Using ProPin is easy, simply drag ...
(Date:5/24/2015)... WI (PRWEB) May 24, 2015 ... Health System CEO - The ... and honored at the fourth annual ... April 15 at Geneva National in ... school): ,     -Badger High School,         Jonathan ...
(Date:5/23/2015)... On May 13, Nithyananda Yoga Foundation organized a ... learned through meditation and initiation at Special Holistic School ... Yogamaatha, a nine-year-old girl from North Carolina, stunned an ... the 2015 Business Advocacy Summit at Capitol Hill in ... In a demonstration that lasted three hours, Yogamaatha was ...
(Date:5/23/2015)... 2015 On Wednesday, May 20, 2015, ... has been the target of a sophisticated cyberattack,” and ... company’s ongoing Information Technology (IT) security efforts in the ... The most notable attack on health insurers was reported ... nation’s second largest health insurer, revealed that they had ...
(Date:5/23/2015)... A live auction will be held to sell over 5,200 ... medical facilities around the United States. Various types of ... exam and much more. , The live auction will ... at 9:00am CDT each day. The equipment is at their ... IL 60160. Anyone can participate in the auction including ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2
... for Childhood Cancer Research (NCCCR), a newly established division of Nemours ... in Wilmington, DE, has secured $1,020,000 in external funding for awards ... ... January 8, 2009-- The research team at the Nemours Center ...
... may reduce risk of cardiovascular disease , , THURSDAY, Jan. ... the millions of American men and women with type ... the day may be symptoms of obstructive sleep apnea, ... diabetics. , Based on strong preliminary evidence linking the ...
... Minnesota receives $20,000 to support local programs as part ... Special Olympics Minnesota recently received $20,000 ... Special Olympics International,s new national program. Project UNIFY is ... States in an effort to promote school communities where ...
... While the U.S. Food and Drug Administration Drug has quickened ... diseases for which new therapeutics are being developed has resulted ... for the Study of Drug Development. , The average time ... years in the 2005-07 period, but longer average clinical phase ...
... Limited (Nasdaq: WCRX ) announced today that ... Conference on Tuesday, January 13, 2009 at 3:00 p.m. ... Boissonneault, President and Chief Executive Officer and Paul Herendeen, ... will be webcast live for all interested parties at ...
... today announced that the second annual Health IT ... content partnership with Health Industry Insights, an IDC company, ... in Phoenix, Arizona from April 29-May 1, 2009. Originally ... moving to the four-diamond Phoenix resort in order to ...
Cached Medicine News:Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 2Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 3Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 4Health News:Doctors Urged to Screen Diabetics for Sleep Apnea 2Health News:Doctors Urged to Screen Diabetics for Sleep Apnea 3Health News:Special Olympics Minnesota Launches Project UNIFY to Energize Youth 2Health News:New drug development still takes 8 years despite faster FDA review, according to Tufts CSDD 2Health News:CrossTech Forums Announces Health IT Insight 2009 Moving to Arizona Grand Resort in Phoenix; Executive Summit to Take Place April 29-May 1 2Health News:CrossTech Forums Announces Health IT Insight 2009 Moving to Arizona Grand Resort in Phoenix; Executive Summit to Take Place April 29-May 1 3
A simple, in-office test for the detection of mononucleosis. Easy to use with fast, accurate results within minutes....
... The Wampole PreVue B. Burgdorferi Antibody ... membrane assay for the qualitative presumptive (first ... to B. burgdorferi in human serum or ... use and relative accuracy make the Wampole ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Medicine Products: